These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8299855)

  • 41. Effects of the PPAR-gamma agonist rosiglitazone on renal haemodynamics and the renin-angiotensin system in diabetes.
    Lansang MC; Coletti C; Ahmed S; Gordon MS; Hollenberg NK
    J Renin Angiotensin Aldosterone Syst; 2006 Sep; 7(3):175-80. PubMed ID: 17094055
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy.
    Bakris GL; Weir MR; DeQuattro V; McMahon FG
    Kidney Int; 1998 Oct; 54(4):1283-9. PubMed ID: 9767545
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The angiotensin II inhibition escape phenomenon in patients with type 2 diabetes and diabetic nephropathy].
    Shamkhlova MSh; Trubitsyna NP; Katsaia GV; Goncharov NP; Malysheva NM; Il'in AV; Nikankina LV; Koshel' LV; Shestakova MV
    Ter Arkh; 2008; 80(1):49-52. PubMed ID: 18326228
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Non-insulin-dependent diabetes mellitus, nephropathy, and the renin system.
    Hollenberg NK
    J Hypertens Suppl; 1997 Dec; 15(7):S7-13. PubMed ID: 9532515
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The renin-angiotensin-aldosterone system and its blockade in diabetic nephropathy: main focus on the role of aldosterone.
    Schjoedt KJ
    Dan Med Bull; 2011 Apr; 58(4):B4265. PubMed ID: 21466768
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
    Schjoedt KJ; Jacobsen P; Rossing K; Boomsma F; Parving HH
    Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The renin angiotensin system in diabetes mellitus. A physiological and therapeutic study.
    Björck S
    Scand J Urol Nephrol Suppl; 1990; 126():1-51. PubMed ID: 2194280
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The state and responsiveness of the renin-angiotensin-aldosterone system in patients with type II diabetes mellitus.
    Price DA; De'Oliveira JM; Fisher ND; Williams GH; Hollenberg NK
    Am J Hypertens; 1999 Apr; 12(4 Pt 1):348-55. PubMed ID: 10232494
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relationship between urinary sodium excretion and serum aldosterone in patients with diabetes in the presence and absence of modifiers of the renin-angiotensin-aldosterone system.
    Libianto R; Jerums G; Lam Q; Chen A; Baqar S; Pyrlis F; Macisaac RJ; Moran J; Ekinci EI
    Clin Sci (Lond); 2014 Jan; 126(2):147-54. PubMed ID: 23875766
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Clinical observation of combined therapeutic effect of prostaglandin E1 and mecobalamin on diabetic peripheral neuropathy].
    Zhu XP; Zhou ZG
    Hunan Yi Ke Da Xue Xue Bao; 2001 Aug; 26(4):343-4. PubMed ID: 12536730
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibition of the renin-angiotensin system: is more better?
    Anderson S; Komers R
    Kidney Int; 2009 Jan; 75(1):12-4. PubMed ID: 19092813
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Metabolism of intravenously administered prostaglandin E1 in patients with peripheral arterial occlusive disease].
    Hesse WH; Rudofsky G; Peskar BA
    Wien Klin Wochenschr; 1991; 103(18):554-7. PubMed ID: 1750222
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The therapeutic effect of lipo PGE1 on diabetic neuropathy-changes in endothelin and various angiopathic factors.
    Itoh Y; Yasui T; Kakizawa H; Makino M; Fujiwara K; Kato T; Imamura S; Yamamoto K; Hishida H; Nakai A; Itoh M; Nagasaka A
    Prostaglandins Other Lipid Mediat; 2001 Oct; 66(3):221-34. PubMed ID: 11577785
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of prostaglandin E1.alpha CD on vibratory threshold determined with the SMV-5 vibrometer in patients with diabetic neuropathy.
    Shindo H; Tawata M; Inoue M; Yokomori N; Hosaka Y; Ohtaka M; Onaya T
    Diabetes Res Clin Pract; 1994 Jul; 24(3):173-80. PubMed ID: 7988349
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Administration of aspirin-dipyridamole reduces proteinuria in diabetic nephropathy.
    Hopper AH; Tindall H; Davies JA
    Nephrol Dial Transplant; 1989; 4(2):140-3. PubMed ID: 2496357
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Endothelin antagonist as add-on treatment for proteinuria in diabetic nephropathy: is there light at the end of the tunnel?
    Ritz E; Wenzel RR
    J Am Soc Nephrol; 2011 Apr; 22(4):593-5. PubMed ID: 21415160
    [No Abstract]   [Full Text] [Related]  

  • 59. Increased inactive renin in diabetes mellitus without evidence of nephropathy.
    Bryer-Ash M; Ammon RA; Luetscher JA
    J Clin Endocrinol Metab; 1983 Mar; 56(3):557-61. PubMed ID: 6337180
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
    Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
    Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.